Back-





                                                       GlyConMedics


           GlyConMedics LLC © 2016                                                   Privacy Policy                                                        info@glyconmedics.com


Professor Tim Hirst
Chairman of the Board of OzStar Therapeutics

Professor Tim Hirst (BSc, PhD) is the Chairman of OzStar Therapeutics and has more than
15 years experience in supporting venture backed start up companies.

Tim was previously the CEO of ANU Connect Ventures, a $30M pre-seed investment fund
established by the Australian National University and the Motor Traders Association (MTAA)
Superannuation Fund.  In that role, he coordinated the formation of a number of start up
ventures and served as the Non-Executive Chairman or a Director of six investee companies
in the biotech, ICT and consumer products sectors.  He has provided advice and support to
a wide range of companies in successfully securing Commonwealth, State & Territory
Government grants from Commercialiation Australia, AusIndustry (COMET and Commercial
Ready) and the Australian Research Council.

Tim's earlier academic roles included Professor and Head of Microbiology at the University
of Bristol and Deputy Vice Chancellor, Research & Innovation at the University of Sydney.
He has been recipient of an EMBO Fellowship and a Senior Research Fellowship from The
Welcome Trust. He has published over 125 research papers and is a named inventor on 6
patent families on immune modulation and vaccines.

Tim is currently also the Executive Chairman of Gamma Vaccines Pty Ltd and an Honorary
Professor in the School of Life Sciences at the Institute of Technology, Bandung.


Dr Nick N Gorgani
Inventor, Founder and CEO

Dr Gorgani (BE, MBBS, MS Drug Dev, PhD), is the inventor of this technology and the
founder and CEO of OzStar Therapeutics (April 2010) and GlyConMedics LLC (March
2013). He has gained multidisciplinary training spanning from chemical engineering to
medicine to immunology and to industrial drug development. He has worked for academic
institutions, hospitals and biotechnology/pharmaceutical companies. N
ick has led numerous
classes of patentable discoveries including, non-inflammatory disposal of pathogens and
dying cells, the discovery of a new biologic for the treatment of RA and AMD, the discovery
of mechanism of action of a small molecule that mediates immune tolerance, the discovery of
a world first-in-class small molecule for the treatment of proteinuria, and the discovery of a
new therapy for the treatment of type 2 diabetes.

N
ick has received numerous awards including Turkish Ministry of Health and Government
scholarships, Australian National University PhD Scholarship, United States Arthritis
Foundation Postdoctoral Fellowship, Scripps Research Institute Society of Fellows
Excellence in Research Award and two grants from the Australian Government. He is a
clinical senior lecturer in the School of Paediatrics and Reproductive Health, University of
Adelaide and at the Department of Medicine, University of Sydney. He has trained a number
of students and postdoctoral fellows and examined a number of PhD and Master’s degree
thesis and peer-reviewed manuscripts for world-leading scientific journals.


Two more directors to be appointed
Board of Directors